Occult Bacteremia in Infants Current controversies and future developments Denise Watt Dec. 6, 2001.

Slides:



Advertisements
Similar presentations
By B. Paul Choate, M.D. Fort Carson MEDDAC. Definitions Fever – elevation of body temperature due to a resetting of the hypothalamic thermoregulatory.
Advertisements

SCVMC Nighttime Curriculum Fever Erin Augustine, MD Alan Schroeder, MD.
Constructing a cost-effectiveness analysis for a vaccine to prevent rotavirus Roseann Dial RN N287E.
Fever 0-3 months What should be done? Donna Moro-Sutherland, MD Pediatric Emergency Medicine Physician WakeMed Health & Hospitals.
“Diagnostic value of procalcitonin in well appearing young febrile infants” Pediatrics 2012; 130:
Community Management of Possible Serious Newborn Infections: Simplified Antibiotic Regimens Bina Valsangkar, MD, MPH Saving Newborn Lives/Save the Children.
Occult Bacteremia. Patients with occult bacteremia do not have clinical evidence other than fever (a systemic response to infection). First described.
Acute Fever in Children
Fever of unknown origin Dr Rafat Mosalli. Different body sites Rectal standardRectal standard Oral  lowerOral  lower Axillary 
Fever in Children Jay Hescock M.D. Assistant Professor of Pediatrics
Infant Fever, What’s Old What’s New Brian R. Moore, M.D., F.A.A.P. PEM Fellowship Director PEM Fellowship Director Assistant Professor, Departments of.
Febrile Child Dr. Steven Blyth Dr. David Johnson.
Fever in Children Year 1 Derby VTS Teaching. Aims and Objectives What is fever? Using 4 case studies we will consider: How to differentiate between children.
BY: DRA.Fatma .s.al zahrani
Febrile Neutropenia Allison Ferrara, MD Princeton Baptist Medical Center Baptist Health Systems Alabama.
All urine is cathed! All temps are rectal Antibiotics 29 DAYS – 2 MONTHS < 28 DAYS WBC 15 Band/Neut >0.2 CSF > 8 WBCs UA > 10 WBCs Stool WBCs/heme CXR.
Pneumonia Sapna Bamrah, MD CDC
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
Hot Topics in Pediatric ID Robert J. Leggiadro, MD Chairman Department of Pediatrics Lincoln Medical Center Professor of Clinical Pediatrics Weill Medical.
Serum Procalcitonin Level and Other Biological Markers to Distinguish Between Bacterial and Aseptic Meningitis in Children A European Multicenter Case.
Microbiologic Surrogate Endpoints in Clinical Trials-IDSA FDA/IDSA/ISAP Workshop April 15, 2004 Sheldon L. Kaplan, MD Baylor College of Medicine Texas.
Fever without source (FWS) in young kids Emergency Medicine Core Rounds October 3, 2002 Dr. Edward Les.
Neonatal Group B Streptococcal Infections
Indication for Otitis Media FDA Vaccine and Related Biologicals Advisory Committee Meeting May 21, 2002 Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria.
Management of the Febrile Infant Risk Minimizers vs. Test Minimizers Steven E. Krug, M.D. SAEM Annual Meeting St. Louis, MO -- May, 2002.
Pediatric Fever in the ED Marc Francis FRCPC R4 PEM Fellow year 1 Consultant Level Physician: Dr Jeff Grant.
Prevention of pneumococcal disease – What are the prospects? Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Allison McGeer,
A pediatric healthcare network A 21st Century Approach to Fever in Infants and Young Children James M Callahan, MD Division of Emergency Medicine Department.
1 Universal Immunization Against Rare Diseases  How much is a child’s life worth?  The individual vs society.
Case 1 You are volunteering in the tent for Grandma’s Marathon and the first wave of runners are finishing. The first patient of the day is a 27 year old.
The Sick Infant: Five Deadly Misconceptions Todd Wylie, MD University of Florida Department of Emergency Medicine June , 2009.
Dipstick Screening for Urinary Tract Infection in Febrile Infants Journal Club Tuesday 15 th July 2014 Charlotte Elder.
Neonates (children less than one month of age) have immature immune systems and are at higher risk for serious complications of bacterial and viral infections,
Insert Program or Hospital Logo Introduction The Respiratory Syncytial virus (RSV) was discovered in 1956 and has been since recognized as one of the most.
Designs to determine the impact of Ab resistance How do we correctly measure the outcomes of antibiotic resistance?
Jennifer L. Hamilton, MD, PhD, FAAFP, Drexel University College of Medicine Sony P. John, MD, Chester County Hospital.
Evaluation of the resistance of bacterial pathogens of synopulmonary infections in children L.Chernyshova F.Lapiy National Medical Academy of Postgraduate.
Predictors of occult pneumococcal bacteremia in young febrile children in the era of pneumococcal conjugated vaccine Mintegi Raso S, Benito Fernández J,
Febrile Child Ping-Wei Chen PGY-1 Emergency Medicine Dr. Lorraine Mabon.
 The overall prevalence of UTI is approximately 2.1 percent in febrile infants but varies widely by race and sex.  Caucasian children have a two- to.
Rule Out UTI. Shaikh N et al. Prevalence of urinary tract infections in childhood. A meta- analysis. Ped Infect Dis J 2008.
Giebink – FDA – 07/11/02 Design Issues in Antimicrobial Treatment Trials of AOM G. Scott Giebink, M.D. Professor of Pediatrics and Otolaryngology Director,
Morning Report August 9, 2010.
1 Otitis Media Results from the Kaiser Permanente Efficacy Trial Steven Black, MD, Henry Shinefield, MD and Bruce Fireman, MS Kaiser Permanente Vaccine.
Validation of a laboratory risk score for the identification of severe bacterial infection in children with fever without source Galetto-Lacour A, Zamora.
Acute Otitis Media To treat or not to treat Gary Kroukamp.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Procalcitonin Use to Predict Bacterial Infection in Febrile Infants Milcent K, Faesch.
Value of white cell count in predicting serious bacterial infection in febrile children under 5 years of age De S, et al. Arch Dis Child 2014;99:493–499.
SCH Journal Club Use of time from fever onset improves the diagnostic accuracy of C-reactive protein in identifying bacterial infections Wednesday 13 th.
Afebrile Infants With UTI and the Risk for Bacteraemia Journal Club Sheffield Children’s Hospital Naheed Maher 7 th January 2015.
Are well infants with urinary tract infections at risk of bacteraemia? Elspeth Ferguson ST6 Paediatrics.
Fever Without Localizing Signs in 2013 Coburn Allen, MD Pediatric Infectious Diseases Pediatric Emergency Medicine Dell Children’s Hospital.
Rashmi Srivastava, MD Department of Child Health
Revising the Decision Analysis For Febrile Children At Risk For Occult Bacteremia In a Future Era of Widespread Pneumococcal Immunization Loren G. Yamamoto,
Prevalence of Bacteremia in Low Risk Patients with Sickle Cell Disease and Fever Shashidhar Marneni, MD Fellow(1 st Year) Pediatric Emergency Medicine.
1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.
Fever in Children Roger M. Barkin, MD. Measurement Definition of fever: 38 C or Definition of fever: 38 C or Sites Sites –Rectal –Tympanic.
Hot Topics in Antibiotic Management of Pediatric CF Lung Disease Mike Tracy, MD Fellow, Pediatric Pulmonary.
PROSPECTIVE COHORT STUDY OF ACUTE PYELONEPHRITIS IN ADULTS: SAFETY OF TRIAGE TOWARDS HOME BASED ORAL ANTIMICROBIAL TREATMENT C. VAN NIEUWKOOP A,*, J.W.
Clinical Infectious Diseases 2012;55(6):764–70 Jan Vydra,1 Ryan M. Shanley,2 Ige George,1 Celalettin Ustun,1 Angela R. Smith,4 Daniel J. Weisdorf,1 and.
Changing Epidemiology of Adult Bacterial Meningitis in Southern Taiwan: A Hospital-Based Study Infection 2008; 36: 15–22 W.-N. Chang, C.-H. Lu, C.-R. Huang,
Fever in the Neonate The Case 3-week old girl whose mother says she “feels warm” and is “acting fussy” ???
Fever in infants: Evaluation by
FEVER WITHOUT LOCALIZING SIGNS
SDMH EMC 2015 Paediatric Fever.
Fever PALS April 24, 2017 Good afternoon and thank you for the opportunity to talk today about the management of febrile young infants. The further along.
Febrile Infant.
Management of the Febrile Young Infant in 2019
Presentation transcript:

Occult Bacteremia in Infants Current controversies and future developments Denise Watt Dec. 6, 2001

Outline background and epidemiology management algorithms evidence for Abx –oral vs. parenteral antibiotic resistance pneumococcal conjugate vaccine

Case 10 month old girl, previously well URI symptoms x 10 days –drinking well, wetting diapers, no N/V/D 2hr hx fever, lethargy, irritability O/E: 180, 42, T39.2, 95% –looks unwell, moaning/crying, HEENT normal, clear BS, some indrawing, CVS normal, abd benign, no rash

Occult Bacteremia: definitions FWS: rectal temp  38  C, no focus, no obvious virus, ‘non-toxic’, no significant underlying illness/immunocompromise OB: FWS and +ve BC 10-20% PED visits for febrile illness 20% febrile children <3yr: no source

Epidemiology: pre-HIB prior to early 1990’s OB incidence 3-12% of FWS –60-85% S.pneumo –5-20% HIB 40% complication rate

Epidemiology: post-HIB incidence of OB (FWS, 3-36 mos, T  39°C) – %, highest age 1-2 yr (Kupperman 1998, Lee 1998) –90-95% S.pneumo –96%  invasive HIB <5 yr (Alpern 2000) –5% non-typhoid Salmonella –others: Neisseria, GAS, GBS, Moraxella, E.coli, S. aureus

Implications of OB 10% SBI if untreated, 17% persistent bacteremia (Harper, Baraff) meningitis: 1% (Baraff), 2.7% (Rothrock) –7.7% mort, 25-30% neuro sequelae overall risk of meningitis in untreated FWS = % natural course of OPB? –96% resolve without Abx (Alpern 2000)

Occult Bacteremia: Subsequent development of focus Dashefsky, J Pediatr 1983., Shapiro, J Pediatr 1986., Woods, AJDC 1990., Baraff, Pediatr Infect Dis J 1992.

Local Microbiology S. pneumo bacteremia rates vary widely across Canada –related to rates of BC drawn –rate in Calgary unknown 30 OPB/yr, 10 SBI/yr, 4-5 meningitis/yr 20 cases invasive HIB/yr (most adults) 139 +BC last year age 1-15 (all comers) –27% contaminants

Predicting OB Hx and PE unreliable –may appear well –subjective vs. objective ‘toxicity’ –YOS >10: sensitivity 77%, specificity 88% –age –fever OPB rare if temp 40 –similar response to defervescence ± OB (Baker 1989, Bonadio 1993)

Predicting OB lab tests insensitive –U/A: most common occult bacterial infection (2% febrile <5yr) –WBC >15x10 9 : sens 67-80%, spec 69% –ANC best predictor (Kuppermann 1998) >10x10 9 : sens 76%, spec 78% –band count unhelpful –one poke most practical (CBC + hold BC)

Blood Cultures 12% +ves return for F/U before BC result, 50% called back (Joffe 1992) –time to +ve = 36hr, time to F/U = 43hr –most pathogens +ve < 18hr  F/U more important than BC 76% SBI or PB called back (Bachur 2000)  BC allow earlier F/U and Rx faster lab techniques coming?

Approach to FWS 3 yr treated differently <1980s, all pt <3mos admitted for septic W/U and empiric Abx low risk criteria developed to avoid hospital admission

Low-risk criteria Rochester criteria 1985 (<2 mos) –NPV 98.9%, PPV 12% Boston criteria 1992 (<3 mos) –NPV 95% Philadelphia criteria 1993 (1-2 mos) –NPV 99.7%, PPV 14%

Baraff “expert consensus” (Pediatrics 1993) –1-3 mos, ‘low risk’ option 1: septic W/U and Abx option 2: urine C&S and observe –3-36 mos, non-toxic: septic W/U if T>39.0 update (Annals Emerg Med 2000) –3-36 mos T  39.0: U/A; T  39.5: WBC  BC (send if >15) –if empiric Abx, do LP!

Bachur 2001 Recursive partitioning model –U/A first step –WBC 20 –T > 39.6 –age < 13d 82% sensitive admit 28% (vs. 53% with Rochester)

Cost-Effectiveness of FWS strategies 1990’s: BC and empiric Abx for all Lee (Pediatrics 2001) –FWS, age 3-36 mos, OPB (1.5%) –meningitis 1° outcome incl. health care and societal costs –CE: CBC + selective BC + Rx if WBC  15 –$30,800 / life-year saved –if rate OPB , less aggressive aproach

Why guidelines need re-evaluation controversy among ‘experts’ lower incidence of OB elimination of HIB cost and complications of tests and Rx pen-resistant S. pneumo not followed anyway (Finklestein 2000) vaccine…..

Antibiotics and FWS Only 2 prospective RCTs with placebo –both small, pre-HIB –Jaffe 1987: no change in SBI Abx  fever, improved appearance large, retrospective study (Harpur 1995) –more focal infection, admissions w/o Abx Abx and meningitis (meta-analysis Baraff) –no Abx 5.8%; oral or parenteral Abx 0.4%

Rothrock 1997: Meta-analysis not all RCTs, underpowered no significant  meningitis significant  SBI (OR 0.35 p=0.003) NNT to prevent 1 meningitis = 651 NNT to prevent 1 SBI = 2190 NNH with Abx for every meningitis prevented = 567  no prospective studies post-HIB

Oral vs. Parenteral Antibiotics Fleisher (1994) –no sign difference in focal infections –  persistent fever with Ctx –not blinded, not intention-to-treat, pre-HIB Rothrock (1997); meta-analysis –meningitis OR=0.67 (oral vs. parenteral) –SBI OR=1.48 closer F/U with parenteral

Risks of Empiric Antibiotics cost (tests, Rx, F/U, hospitalization) side effects discomfort of tests, treatment altered presentation (Rothrock 1992) development of resistant strains missed/partially Rx focal infections parental preference? –will accept small risk of SBI vs. discomfort of tests & Rx (Kramer, Oppenheim)

Penicillin-resistant Pneumococcus Castillo –San Diego : 18% pen resistance –14% int. resistance 1991, 42% in 1998 –no difference in mortality –NS increased resistance with prior Abx use

Pen and Cephalosporin resistance Silverstein –11 year review: 8% resistance –no diff in outcome, LOS in pen-resistant –Ceftriaxone-resistant: more focal infection, more LPs, more febrile at F/U, more admitted (NS),  HR and temp at presentation

Antibiotic resistant Pneumococcus in Calgary 15% pen resistance <2% amoxicillin resistance 10% Cefuroxime resistance 3-4% Ceftriaxone resistance –need higher MIC for CNS  clinically, has not been an issue

Conjugate Pneumococcal Vaccine heptavalent, 4 doses: 2,4,6,12-15 mos FDA approval Feb 2000 (Prevnar) 3 RCTs of safety and immunogenicity –Rennels (1998) –Shinefield (1999) –Black (2000) efficacy 97%, intention-to-treat 94% including ALL S.pneumo serotypes: 89% similar SE as DPTP/HIB, none severe

Pneumococcal Vaccine significantly  OM Black: ongoing trial on herd immunity long-term efficacy? strain selection? Bottom line: will significantly decrease burden of S.pneumo disease likely lag time to change practices

Impact Of Prevnar in N. California ~33,000 with ≥1 dose Feb 2000-Mar 2001 Shinefield et al. 3rd Int’l PID Conference Monterey, 2001

Pneumococcal Vaccine: Cost Effectiveness Lieu (JAMA 2000) –cost < savings if each dose <$46 (US) –present: $56 (US) = $278,000/life-yr saved –>2x savings for society vs. health payer  $760 million/3.8M infants/yr in US most from parental work loss,  productivity Calgary: $110/dose ($84 at ACH) current immunization budget: $17M/yr cost of SP vaccine: $13M/yr

Occult Bacteremia: Summary age, temp, appearance important don’t forget U/A save labs for ‘unwell’ faster BC techniques in distant future F/U most important tool empiric Abx have very limited role no clear evidence favouring parenteral

Occult Bacteremia: Summary II antibiotic-resistance is rising; impact small in Calgary vaccine WILL change the face of FWS –‘It’s viral!’ until then, the controversy continues! –“Are you a risk-minimizer or test- minimizer?” (Green, Rothrock. Annals Emerg Med. 1999)

Case revisited WBC 14.9 –ANC 8.3 BC +ve S.pneumo in 24hr (pen I) R/A: looks well, T 38.5 Mgt?

Case cont. Ceftriaxone IV F/U ID clinic: –well-looking –Ctx IV x 3 days, then Amoxil x 7 days

QUESTIONS ?